H. Infanta Leonor
Madrid, Spain
NCT Number: NCT05405751
Implementation of a model for access and retention of HIV care for vulnerable and excluded population using a mobile screening unit and a strategy of diagnosis and initiation of treatment with Bictegravir (BIC) 50 mg/ Emtricitabine (FTC) 200 mg / Tenofovir Alafenamide (TAF) 25 mg.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Madrid, Spain
The use of a mobile unit to reach vulnerable HIV-infected people with poor access to the health care system and starting/restarting on the same day ("simplified same day test and treat strategy") is feasible, effective and safe and will allow these people to have a rapid access to ART and long-term follow-up and health care for HIV.
At the screening visit the patient will sign the informed consent form, revise the clinical history and ensure compliance with criteria. A history of drug abuse, complete physical examination, pregnancy test, rapid hepatitis C test, questionnaires and social situation will be collected from the patient.
At the basal visit the patients enrolled in the study will collect lab test (blood count, biochemistry, coagulation, serology, inmunology and virology), vital signs and directed physical examination, concomitant medication and adverse events.
After the basal visit the patient will be followed up on visits week 4, 12, 24, 48 and last visit 50 as follow up safety visit.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients enrolled in the study and accessing the HIV consultation will start treatment with BIKTARVY on the day of enrollment. Medication will be provided by the sponsor and dispensed through the pharmacy service. The drug will be delivered to the patient with a delegated person outside the hospital environment or it will be the patient himself who picks up the medication.
Time frame: 24-48 weeks
Proportion of subjects making visits at weeks 24 and 48.
Time frame: Baseline, week 4, week 12, week 24 and week 48
Proportion of participants with HIV viral load <50 copies/ml throughout the study
Fundacion SEIMC-GESIDA
Other
Simplified Model of Linkage and Retention to Healthcare System, Using a Mobil Unit and a Same-day Test and Treat Approach Among Excluded Population.
Acronym: SIMPLIFIED
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03048422
Blood-Borne Infections, Communicable Diseases
Jacksonville, Florida, United States
View Trial DetailsNCT05388474
Blood-Borne Infections, Communicable Diseases
Los Angeles, California, United States
View Trial DetailsNCT03284710
Blood-Borne Infections, Communicable Diseases
Maputo, Mozambique
View Trial DetailsNCT02591420
Blood-Borne Infections, Communicable Diseases
Kericho, Kenya
View Trial Details